EUVIMEDEUVIMED entdecken
Editorial

The Landscape of Medical AI in China

Yue Qiu iD, Weizhi Ma iD, Haibo Wang iD, Yih-Chung Tham iD, Tien Yin Wong iD

NEJM AI · 26.06.2025 · 2 (7)

DOI: 10.1056/aip2401234 ↗

Kurz gefasst

Editorial in der Zeitschrift NEJM AI, erschienen am 26.06.2025. Verfasst von Yue Qiu und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Healthcare Management, Tsinghua Medicine, Tsinghua University, Beijing. Hauptthemen laut MEDLINE: Artificial Intelligence, Biomedical Research. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AbstractChina has achieved significant progress in the medical AI field in recent years. However, the international community may be unaware of the scope and extent of medical AI innovations in China. In this perspective, we provide data on the landscape of medical AI in China, covering research focus areas, key players from academia and industry, and the main drivers of medical AI development. We provide insights into these trends relative to those seen in the United States. The number of medical AI-related publications from China has exceeded that from the United States in the past 2 years. Although both China and the United States prioritize technical development in their publications, followed by clinical disciplines, the United States had a more balanced focus between technical and clinical research. The Chinese Academy of Sciences and major universities affiliated with top hospitals are the predominant players. Regarding patents and revenue, several large Chinese medical technology companies are emerging as influential players, but they continue to lag behind large U.S. technology companies. Rapid increases in governmental funding, access to computational power, and optimization of an AI regulatory framework have become the main drivers of China's advancements in medical AI. Despite this progress, key challenges remain, including fragmented data sources and limited integration of AI into clinical workflow. Addressing these barriers will allow China to contribute to global medical AI development. (Funded by the National Key Research and Development Program of China, grant number 2022YFC2502800, and others.).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Artificial IntelligenceBiomedical ResearchHumansAcademiaChinaUnited States

Autor:innen und Institutionen

  • School of Healthcare Management, Tsinghua Medicine, Tsinghua University, Beijing.
  • Institute for AI Industry Research, Tsinghua University, Beijing.
  • Research Centre of Big Data and Artificial Intelligence for Medicine, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
  • Singapore Eye Research Institute, Singapore National Eye Centre.
  • Centre for Innovation and Precision Eye Health, Department of Ophthalmology, Yong Loo Lin School of Medicine, National University of Singapore.
  • Eye Academic Clinical Program (EYE ACP), Duke-NUS Medical School, Singapore.

ORCID-Profile: Yue Qiu, Weizhi Ma, Haibo Wang, Yih-Chung Tham, Tien Yin Wong

Zitieren

APA

Qiu, Y., Ma, W., Wang, H., Tham, Y. C., & Wong, T. Y. (2025). The Landscape of Medical AI in China. NEJM AI, 2(7). https://doi.org/10.1056/aip2401234

Vancouver

Qiu Y, Ma W, Wang H, Tham YC, Wong TY. The Landscape of Medical AI in China. NEJM AI. 2025;2(7). doi:10.1056/aip2401234

BibTeX
@article{Qiu2025,
  author = {Qiu, Yue and Ma, Weizhi and Wang, Haibo and Tham, Yih-Chung and Wong, Tien Yin},
  title = {The Landscape of Medical AI in China},
  journal = {NEJM AI},
  year = {2025},
  volume = {2},
  number = {7},
  doi = {10.1056/aip2401234}
}
Kostenlos starten →